Exosome Diagnostics, Life Technologies Ink Agreement for Oncology Dx Program | GenomeWeb

NEW YORK (GenomeWeb News) – Exosome Diagnostics today said that it has signed an agreement with Life Technologies to use the Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument for its exosome biofluid in vitro diagnostics program.

Exosome will validate the 7500 platform with exosome biofluid RNA isolation kits in clinical trials beginning this year in brain and prostate cancer. Terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.